Journal Management System
ScopeMed is an
Online Journal/Article Management system
that can enable all of the operations of
the editorial functions of a journal.
Home  |   Add your Journal  |   Features  |   Job Opportunities/Service Offers  |   Journal List
Author Login | Reviewer Login | Editor Login
Search  

Medical Archives
Periodical of AVICENA, d.o.o., Sarajevo
Journal Home Page
ISSN: 0350-199X (Print)
ISSN: 1986-5961 (Online)
Language: [ English ]  
News / Announcements

  » Volume 68, Issue 3
      pp. 156-222
  » Volume 68, Issue 2
      pp. 76-146
  » Volume 68, Issue 1
      pp. 4-70

 

Open Access

Original Research



The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes

Zelija Velija-Asimi, Sebija Izetbegovic, Jasenko Karamehic, Jozo Coric, Mirsad Panjeta, Amra Macic-Dzankovic, Jasminka Djelilovic-Vranic, mela Dizdarevic-Bostandzic.

Abstract
Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antihyperglycemic drugs that block degradation of incretin hormones. Goal: To assess the effects of treatment with DPP-4 inhibitors on glucoregulation and body weight in obese patients with type 2 diabetes mellitus. Patients and methods: The study included 9 females and 9 males with type 2 diabetes (n=18), BMI=31.24±2,26 kg/m2, mean age 58 ±6,8 years. The patients have been thoroughly evaluated before treatment, and 6 months after treatment with DPP-4 inhibitor (sitagliptin) in combination with metformin. Results: After 6 months of treatment with DPP-4 inhibitors in combination with metformin HbAlc (-1,49%)., FBG (-3.75 mmol/L) and PBG (-5.79 mmol/L) significantly reduced (p=0.000). Mean body weight also significantly reduced (-12.5%; p=0.000). Reduction of mean fasting insulin was 5.46 mIU/L or 27% (p=0.000). Mean HOMA-IR change was −1.64 (p=0.000). Also there was significant decreasing of systolic blood pressure (p=0.001), cholesterol (p=0.004), triglycerides (p=0.001), LDL (p=0.002) and increasing of HDL (p=0.002). Hypoglycaemia was not registered in any of the patients. Conclusion: These results show that in obese patients with type 2 diabetes, DPP-4 inhibitors treatment in combination with metformin was associated with improvements in glycaemic control, and a reduction in body weight.

Key words: Dipeptidyl peptidase-4 inhibitors, metformin, type 2 diabetes, obesity.


ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Export to
Export to
Related Records
 Articles by Zelija Velija-Asimi
Articles by Sebija Izetbegovic
Articles by Jasenko Karamehic
Articles by Jozo Coric
Articles by Mirsad Panjeta
Articles by Amra Macic-Dzankovic
Articles by Jasminka Djelilovic-Vranic
Articles by mela Dizdarevic-Bostandzic
on IndexScholar Fulltext
on Google
on Google Scholar
Article Statistics
 Viewed: 720
Downloaded: 164
(Last 7 Days: 3)
Cited: 0
Emailed: 0

REFERENCES
1. Kalra S. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes. J Assoc Physicians India. 2011; 59: 237-245.
 
2. Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med. 2010; 122(3): 71-80. http://dx.doi.org/10.3810/pgm.2010.05.2144   [Pubmed]       
 
3. Wirth A. Anti-diabetic drugs. Weight reduction as a favourable side effect. Internist (Berl). 2011; 52(4): 451-461.
 
4. Cornell S. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. J Clin Pharm Ther. 2012; 37(5): 510-524. http://dx.doi.org/10.1111/j.1365-2710.2012.01342.x   [Pubmed]       
 
5. Solun B, Marcoviciu D, Dicker D. Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system. Curr Cardiol Rep. 2013; 15(8): 382. http://dx.doi.org/10.1007/s11886-013-0382-2   [Pubmed]       
 
6. Scheen AJ. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med. 2013; 125(3): 7-20. http://dx.doi.org/10.3810/pgm.2013.05.2659   [Pubmed]       
 
7. De Fronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012; 97(5): 1615-1622. http://dx.doi.org/10.1210/jc.2011-2243   [Pubmed]       
 

How to Cite this Article
Pubmed Style

Velija-Asimi Z, Izetbegovic S, Karamehic J, Coric J, Panjeta M, Macic-Dzankovic A, Djelilovic-Vranic J, . The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes . Med Arh. 2013; 67(5): 365-367. doi:10.5455/medarh.2013.67.365-367



Web Style

Velija-Asimi Z, Izetbegovic S, Karamehic J, Coric J, Panjeta M, Macic-Dzankovic A, Djelilovic-Vranic J, . The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes . www.scopemed.org/?mno=46177 [Access: July 29, 2014]. doi:10.5455/medarh.2013.67.365-367



AMA (American Medical Association) Style

Velija-Asimi Z, Izetbegovic S, Karamehic J, Coric J, Panjeta M, Macic-Dzankovic A, Djelilovic-Vranic J, . The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes . Med Arh. 2013; 67(5): 365-367. doi:10.5455/medarh.2013.67.365-367



Vancouver/ICMJE Style

Velija-Asimi Z, Izetbegovic S, Karamehic J, Coric J, Panjeta M, Macic-Dzankovic A, Djelilovic-Vranic J, . The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes . Med Arh. (2013), [cited July 29, 2014]; 67(5): 365-367. doi:10.5455/medarh.2013.67.365-367



Harvard Style

Velija-Asimi, Z., Izetbegovic, S., Karamehic, J., Coric, J., Panjeta, M., Macic-Dzankovic, A., Djelilovic-Vranic, J. & (2013) The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes . Med Arh, 67 (5), 365-367. doi:10.5455/medarh.2013.67.365-367



Turabian Style

Velija-Asimi, Zelija, Sebija Izetbegovic, Jasenko Karamehic, Jozo Coric, Mirsad Panjeta, Amra Macic-Dzankovic, Jasminka Djelilovic-Vranic, and mela Dizdarevic-Bostandzic. 2013. The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes . Medical Archives, 67 (5), 365-367. doi:10.5455/medarh.2013.67.365-367



Chicago Style

Velija-Asimi, Zelija, Sebija Izetbegovic, Jasenko Karamehic, Jozo Coric, Mirsad Panjeta, Amra Macic-Dzankovic, Jasminka Djelilovic-Vranic, and mela Dizdarevic-Bostandzic. "The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes ." Medical Archives 67 (2013), 365-367. doi:10.5455/medarh.2013.67.365-367



MLA (The Modern Language Association) Style

Velija-Asimi, Zelija, Sebija Izetbegovic, Jasenko Karamehic, Jozo Coric, Mirsad Panjeta, Amra Macic-Dzankovic, Jasminka Djelilovic-Vranic, and mela Dizdarevic-Bostandzic. "The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes ." Medical Archives 67.5 (2013), 365-367. Print. doi:10.5455/medarh.2013.67.365-367



APA (American Psychological Association) Style

Velija-Asimi, Z., Izetbegovic, S., Karamehic, J., Coric, J., Panjeta, M., Macic-Dzankovic, A., Djelilovic-Vranic, J. & (2013) The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes . Medical Archives, 67 (5), 365-367. doi:10.5455/medarh.2013.67.365-367







Total Download: 164.610
(for Medical Archives)
Total Submission during last 24 hours: 168


» For Authors




Become Reviewer


» Login Area




Follow ScopeMed on Twitter

ScopeMed Home | About ScopeMed | Contact Us | Terms & Conditions | Privacy Policy
The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Service of SAGEYA Publishing for Scientific Publications. Copyright © ScopeMed® International Medical Journal Management and Indexing System.